These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38636709)

  • 1. Using the genomic adjusted radiation dose (GARD) to personalize the radiation dose in nasopharyngeal cancer.
    Chiang CL; Chan KSK; Li H; Ng WT; Chow JCH; Choi HCW; Lam KO; Lee VHF; Ngan RKC; Lee AWM; Eschrich SA; Torres-Roca JF; Wong JWH
    Radiother Oncol; 2024 Jul; 196():110287. PubMed ID: 38636709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemotherapy.
    Teo PM; Chan AT; Lee WY; Leung TW; Johnson PJ
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):261-71. PubMed ID: 10030248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma.
    Kong L; Gao J; Hu J; Hu W; Guan X; Lu R; Lu JJ
    Chin J Cancer; 2016 Dec; 35(1):101. PubMed ID: 28007028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis.
    Scott JG; Sedor G; Ellsworth P; Scarborough JA; Ahmed KA; Oliver DE; Eschrich SA; Kattan MW; Torres-Roca JF
    Lancet Oncol; 2021 Sep; 22(9):1221-1229. PubMed ID: 34363761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management.
    Ahmed KA; Liveringhouse CL; Mills MN; Figura NB; Grass GD; Washington IR; Harris EE; Czerniecki BJ; Blumencranz PW; Eschrich SA; Scott JG; Diaz R; Torres-Roca JF
    EBioMedicine; 2019 Sep; 47():163-169. PubMed ID: 31416721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
    Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
    Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
    Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
    Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
    Kong L; Zhang YW; Hu CS; Guo Y
    Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience.
    Kam MK; Teo PM; Chau RM; Cheung KY; Choi PH; Kwan WH; Leung SF; Zee B; Chan AT
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1440-50. PubMed ID: 15590175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.
    Scott JG; Berglund A; Schell MJ; Mihaylov I; Fulp WJ; Yue B; Welsh E; Caudell JJ; Ahmed K; Strom TS; Mellon E; Venkat P; Johnstone P; Foekens J; Lee J; Moros E; Dalton WS; Eschrich SA; McLeod H; Harrison LB; Torres-Roca JF
    Lancet Oncol; 2017 Feb; 18(2):202-211. PubMed ID: 27993569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How successful is high-dose (> or = 60 Gy) reirradiation using mainly external beams in salvaging local failures of nasopharyngeal carcinoma?
    Teo PM; Kwan WH; Chan AT; Lee WY; King WW; Mok CO
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):897-913. PubMed ID: 9531376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrinsic radiosensitivity, genomic-based radiation dose and patterns of failure of penile cancer in response to adjuvant radiation therapy.
    Yuan Z; Grass GD; Azizi M; Ahmed KA; Yoder GSJ; Welsh EA; Fulp WJ; Dhillon J; Torres-Roca JF; Giuliano AR; Spiess PE; Johnstone PA
    Rep Pract Oncol Radiother; 2019; 24(6):593-599. PubMed ID: 31719799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy followed by concurrent chemo-radiation therapy in locally advanced nasopharyngeal carcinoma.
    Al-Amro A; Al-Rajhi N; Khafaga Y; Memon M; Al-Hebshi A; El-Enbabi A; El-Husseiny G; Radawi A; Belal A; Allam A; El-Sebaie M
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):508-13. PubMed ID: 15890594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fractionated stereotactic radiotherapy with vagina carotica protection technique for local residual nasopharyngeal carcinoma after primary radiotherapy.
    Liu F; Xiao JP; Xu YJ; Zhang Y; Xu GZ; Gao L; Yi JL; Luo JW; Huang XD; Huan FK; Fang H; Wan B; Li YX
    Chin Med J (Engl); 2012 Jul; 125(14):2525-9. PubMed ID: 22882934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma.
    Kwong DL; Sham JS; Leung LH; Cheng AC; Ng WM; Kwong PW; Lui WM; Yau CC; Wu PM; Wei W; Au G
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):374-81. PubMed ID: 16213105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prospective 10-Year Observational Study of Reduction of Radiation Therapy Clinical Target Volume and Dose in Early-Stage Nasopharyngeal Carcinoma.
    Miao J; Di M; Chen B; Wang L; Cao Y; Xiao W; Wong KH; Huang L; Zhu M; Huang H; Huang S; Han F; Deng X; Xiang Y; Lv X; Xia W; Tan SH; Wee JTS; Guo X; Chua MLK; Zhao C
    Int J Radiat Oncol Biol Phys; 2020 Jul; 107(4):672-682. PubMed ID: 32272183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of a genome-based model for adjusting radiotherapy dose (GARD) in patients with locally advanced rectal cancer.
    Xia H; Li Z; Lin Y; Lin Y; Zeng L; Xu B; Yao Q; Zheng R
    Sci Rep; 2024 Sep; 14(1):21572. PubMed ID: 39284851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma.
    Lu TX; Mai WY; Teh BS; Zhao C; Han F; Huang Y; Deng XW; Lu LX; Huang SM; Zeng ZF; Lin CG; Lu HH; Chiu JK; Carpenter LS; Grant WH; Woo SY; Cui NJ; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):682-7. PubMed ID: 14967420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinicogenomic model including GARD predicts outcome for radiation treated patients with HPV+ oropharyngeal squamous cell carcinoma.
    Ho E; De Cecco L; Cavalieri S; Sedor G; Hoebers F; Brakenhoff RH; Scheckenbach K; Poli T; Yang K; Scarborough JA; Campbell S; Koyfman S; Eschrich SA; Caudell JJ; Kattan MW; Licitra L; Torres-Roca JF; Scott JG
    medRxiv; 2023 Sep; ():. PubMed ID: 37745365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation dose escalation for locally advanced nasopharyngeal carcinoma patients with local and/or regional residual lesions after standard chemoradiotherapy: a non-randomized, observational study.
    Jin T; Liu NF; Jin QF; Hua YH; Chen XZ
    Radiat Oncol; 2022 Nov; 17(1):176. PubMed ID: 36345003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.